ImmuPharma plc (LON:IMM – Get Free Report) was up 27.6% during trading on Saturday . The company traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.35 ($0.04). Approximately 8,992,934 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 23,308,711 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Price Performance
The stock has a market capitalization of £13.95 million, a PE ratio of -335.00 and a beta of 1.53. The company’s 50 day moving average price is GBX 1.59 and its two-hundred day moving average price is GBX 1.69.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Stock Market Upgrades: What Are They?
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Where to Find Earnings Call Transcripts
- Oilfield Leader SLB: An AI Name You Need to Know
- How to Capture the Benefits of Dividend Increases
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
